Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03199053




Registration number
NCT03199053
Ethics application status
Date submitted
22/06/2017
Date registered
26/06/2017
Date last updated
5/09/2021

Titles & IDs
Public title
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old
Scientific title
A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age
Secondary ID [1] 0 0
2015-005042-66
Secondary ID [2] 0 0
D1680C00019
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dapagliflozin
Treatment: Drugs - Saxagliptin
Treatment: Drugs - Placebo

Experimental: Low dose Dapagliflozin - Oral route. Start with a low dose of dapagliflozin administered once daily and remain on the low dose regardless of your HbA1c at week 12.

Experimental: Low dose/high dose Dapagliflozin - Oral route. Start with a low dose of Dapagliflozin administered once daily and up titrate to the high dose Dapagliflozin administered once daily if HbA1c >= 7% at week 12

Experimental: Low dose Saxagliptin - Oral route. Start with a low dose of saxagliptin administered once daily and remain on the low dose regardless of your HbA1c at week 12

Experimental: Low dose/high dose Saxagliptin - Oral route. Start with a low dose of saxagliptin administered once daily and up titrate to the high dose if HbA1c >= 7% at week 12

Placebo Comparator: Placebo arm - Oral route. Placebo tablets administered for 52 weeks


Treatment: Drugs: Dapagliflozin
Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily

Treatment: Drugs: Saxagliptin
Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily

Treatment: Drugs: Placebo
Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in HbA1c at Week 26 - To determine if there will be a greater mean reduction from baseline in HbA1c achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin 5 mg or saxagliptin 2.5 mg (with titration to the high-dose for those who do not achieve the glycemic target of HbA1c < 7% at 12 weeks) compared to placebo in pediatric T2DM subjects with HbA1c levels of 6.5 to 10.5% on diet and exercise and metformin (IR or XR), insulin, or metformin (IR or XR) plus insulin.
Timepoint [1] 0 0
26 weeks
Secondary outcome [1] 0 0
Change from baseline in Fasting Plasma Glucose at Week 26 - To determine if there will be a greater mean reduction from baseline in Fasting Plasma Glucose (FPG) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin 5 mg or saxagliptin 2.5 mg (with titration to the high-dose for those who do not achieve the glycemic target of HbA1c <7% at 12 weeks) compared to placebo in pediatric T2DM subjects with HbA1c of 6.5 to 10.5% on diet and exercise and metformin (IR or XR), insulin, or metformin (IR or XR) plus insulin
Timepoint [1] 0 0
26 weeks
Secondary outcome [2] 0 0
Percentage of subjects with baseline HbA1c = 7%, who achieve an HbA1c level < 7.0% at Week 26 - To compare the percentage of subjects with baseline HbA1c = 7% who achieve an HbA1c level < 7.0% after 26 weeks of oral double-blind add-on therapy of dapagliflozin 5 mg or saxagliptin 2.5 mg (with titration to the high-dose for those who do not achieve the glycemic target of HbA1c <7% at 12 weeks) versus placebo in pediatric T2DM subjects with HbA1c of 6.5 to 10.5% on diet and exercise and metformin (IR or XR), insulin, or metformin (IR or XR) plus insulin
Timepoint [2] 0 0
26 weeks

Eligibility
Key inclusion criteria
- Signed Written Informed Consent

- Target Population

- Previously diagnosed with Type 2 Diabetes Mellitus by World Health Organization/ADA
criteria

- HbA1c between 6.5% and 10.5% obtained at screening.

- Currently on diet and exercise and stable dose of at least 1000 mg metformin (IR or
XR) for a minimum of 8 weeks, or stable dose of insulin for a minimum of 8 weeks, or a
stable combination of at least 1000 mg metformin (IR or XR) and insulin for a minimum
of 8 weeks prior to randomization. For those children on insulin, investigators will
confirm that attempts at removing insulin from the subject's therapeutic regimen had
been previously made but had not been successful.

- Age and Reproductive Status

- Male and female patients eligible if 10 years of age, up to but not including 18 years
of age at the time of enrollment/screening. At least 30% of total subjects will be
between the ages of 10 and 14 years and at least one third, but no more than two
thirds, female subjects.

- Women of childbearing potential must have a negative pregnancy test within 24 hours
prior to the start of study drug.

- Women must not be breastfeeding.

- Women of childbearing potential must agree to follow instructions for method(s) of
contraception for the duration of treatment with study drugs: saxagliptin, and
dapagliflozin, plus 5 half-lives of study drugs or 30 days (whichever is longer), plus
30 days (duration of ovulatory cycle) for a total of 60 days post treatment
completion.
Minimum age
10 Years
Maximum age
18 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Target Disease Exceptions

- Presence of Type 1 diabetes, as demonstrated by Preexisting diagnosis of Type 1
diabetes,

- Previous diagnosis of monogenic etiology of Type 2 diabetes

- Diabetes ketoacidosis (DKA) within 6 months of screening

- Current use of the following medications for the treatment of diabetes, or use within
the specified timeframe prior to screening for the main study:

- Eight weeks: sulfonylureas, alpha glucosidase inhibitors, metiglinide, oral or
injectable incretins or incretin mimetics, other antidiabetes medications not
otherwise specified.

- Sixteen weeks: thiazolidinediones, DPP-4 inhibitors (with no reported medication
related AEs related to DPP-4 inhibitors), sodium glucose cotransporter-2 (SGLT-2)
inhibitors (with no reported medication related AEs related to SGLT-2 inhibitors)

- Initiation or discontinuation of prescription or non-prescription weight loss drugs
within 8 weeks of screening. Use of prescription or non-prescription weight loss drugs
must be stable during the study.

- Medical History and Concurrent Diseases

- Pregnant, positive serum pregnancy test, planning to become pregnant during the
clinical trials, or breastfeeding

- History of unstable or rapidly progressive renal disease

- History of unresolved vesico-ureteral reflux

- History of or current, acute or chronic pancreatitis

- History of hemoglobinopathy, with the exception of sickle cell trait or thalassemia
minor; or chronic or recurrent hemolysis

- Malignancy within 5 years of the screening visit (with the exception of treated basal
cell or treated squamous cell carcinoma)

- Replacement or chronic systemic corticosteroid therapy, defined as any dose of
systemic corticosteroid taken for > 4 weeks within 3 months prior to the Day 1 visit

- Physical and Laboratory Test Findings

- Abnormal renal function,

- An abnormal thyroid-stimulating hormone (TSH) value at enrollment will be further
evaluated for free T4. Subjects with abnormal free T4 values will be excluded.

- Hematuria (confirmed by microscopy at screening) with no explanation as judged by the
Investigator up to randomization.

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2× upper limit of
normal (ULN), or clinically significant hepatic disease.

- Serum total bilirubin (TB) > 2x ULN unless exclusively caused by Gilbert's syndrome

- Positive serologic evidence of current infectious liver disease including anti
hepatitis A virus (HAV) (IgM), hepatitis B surface antigen (HBsAg), or anti hepatitis
C virus (HCV). Patients who have isolated positive anti-hepatitis B surface antibodies
may be included.

- Anemia of any etiology

- Volume-depleted subjects.

- Allergies and Adverse Drug Reaction

- Known allergy, sensitivity or contraindication to any study drug or its
excipient/vehicle

- Other Exclusion Criteria

- Subject is currently abusing alcohol or other drugs or has done so within the last 6
months prior to the screening visit.

- Prisoners or subjects who are involuntarily incarcerated. (Note: under certain
specific circumstances a person who has been imprisoned may be included or permitted
to continue as a subject. Strict conditions apply and Sponsor/designee approval is
required.)

- Subjects who are compulsorily detained for treatment of either a psychiatric or
physical (e.g., infectious disease) illness.

- Psychiatric or cognitive disorder that will, in the opinion of investigators, limit
the subject's ability to comply with the study medications and monitoring.

- Subjects who have contraindications to therapy as outlined in the saxagliptin and
dapagliflozin Investigator Brochure or local package inserts.

- Participation and receiving IP in another clinical study during the prior 3 months

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Blacktown
Recruitment hospital [2] 0 0
Research Site - Kanwal
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2259 - Kanwal
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Idaho
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
New Jersey
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Tennessee
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
United States of America
State/province [10] 0 0
Virginia
Country [11] 0 0
Argentina
State/province [11] 0 0
Buenos Aires
Country [12] 0 0
Argentina
State/province [12] 0 0
Caba
Country [13] 0 0
Argentina
State/province [13] 0 0
Ciudad Autonoma de Buenos Aire
Country [14] 0 0
Argentina
State/province [14] 0 0
Ciudad de Buenos Aires
Country [15] 0 0
Argentina
State/province [15] 0 0
San Miguel de Tucuman
Country [16] 0 0
Argentina
State/province [16] 0 0
San Miguel de Tucumán
Country [17] 0 0
Brazil
State/province [17] 0 0
Belem
Country [18] 0 0
Brazil
State/province [18] 0 0
Brasilia
Country [19] 0 0
Brazil
State/province [19] 0 0
Campinas
Country [20] 0 0
Brazil
State/province [20] 0 0
Curitiba
Country [21] 0 0
Brazil
State/province [21] 0 0
Fortaleza
Country [22] 0 0
Brazil
State/province [22] 0 0
Passo Fundo
Country [23] 0 0
Brazil
State/province [23] 0 0
Porto Alegre
Country [24] 0 0
Brazil
State/province [24] 0 0
Ribeirão Preto
Country [25] 0 0
Brazil
State/province [25] 0 0
Santa Maria
Country [26] 0 0
Brazil
State/province [26] 0 0
Sao Paulo
Country [27] 0 0
Brazil
State/province [27] 0 0
Uberaba
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
Chile
State/province [29] 0 0
San Bernardo
Country [30] 0 0
Chile
State/province [30] 0 0
Santiago
Country [31] 0 0
Colombia
State/province [31] 0 0
Armenia
Country [32] 0 0
Colombia
State/province [32] 0 0
Barranquilla
Country [33] 0 0
Colombia
State/province [33] 0 0
Bogotá
Country [34] 0 0
Colombia
State/province [34] 0 0
Medellin
Country [35] 0 0
Finland
State/province [35] 0 0
Kuopio
Country [36] 0 0
Finland
State/province [36] 0 0
Seinäjoki
Country [37] 0 0
Finland
State/province [37] 0 0
Tampere
Country [38] 0 0
India
State/province [38] 0 0
Ahmedabad
Country [39] 0 0
India
State/province [39] 0 0
Aurangabad
Country [40] 0 0
India
State/province [40] 0 0
Bangalore
Country [41] 0 0
India
State/province [41] 0 0
Bikaner
Country [42] 0 0
India
State/province [42] 0 0
Chandigarh
Country [43] 0 0
India
State/province [43] 0 0
Coimbatore
Country [44] 0 0
India
State/province [44] 0 0
Hyderabad
Country [45] 0 0
India
State/province [45] 0 0
Kolkata
Country [46] 0 0
India
State/province [46] 0 0
Kozhikode
Country [47] 0 0
India
State/province [47] 0 0
Nagpur
Country [48] 0 0
India
State/province [48] 0 0
Nashik
Country [49] 0 0
India
State/province [49] 0 0
Pune
Country [50] 0 0
India
State/province [50] 0 0
Vadodara
Country [51] 0 0
India
State/province [51] 0 0
Visakhapatnam
Country [52] 0 0
Israel
State/province [52] 0 0
Haifa
Country [53] 0 0
Italy
State/province [53] 0 0
Ancona
Country [54] 0 0
Italy
State/province [54] 0 0
Modena
Country [55] 0 0
Italy
State/province [55] 0 0
Napoli
Country [56] 0 0
Italy
State/province [56] 0 0
Roma
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Daejeon-si
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Incheon
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Seongnam-si
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Seoul
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Wonju-si
Country [62] 0 0
Malaysia
State/province [62] 0 0
George Town
Country [63] 0 0
Malaysia
State/province [63] 0 0
Ipoh
Country [64] 0 0
Malaysia
State/province [64] 0 0
Johor Bahru
Country [65] 0 0
Malaysia
State/province [65] 0 0
Klang
Country [66] 0 0
Malaysia
State/province [66] 0 0
Kota Kinabalu
Country [67] 0 0
Malaysia
State/province [67] 0 0
Kuala Lumpur
Country [68] 0 0
Malaysia
State/province [68] 0 0
Kuching
Country [69] 0 0
Malaysia
State/province [69] 0 0
Melaka
Country [70] 0 0
Malaysia
State/province [70] 0 0
Putrajaya
Country [71] 0 0
Malaysia
State/province [71] 0 0
Seri Manjung
Country [72] 0 0
Malaysia
State/province [72] 0 0
Taiping
Country [73] 0 0
Mexico
State/province [73] 0 0
Boca del Rio
Country [74] 0 0
Mexico
State/province [74] 0 0
Celaya
Country [75] 0 0
Mexico
State/province [75] 0 0
Ciudad Madero
Country [76] 0 0
Mexico
State/province [76] 0 0
Cuernavaca
Country [77] 0 0
Mexico
State/province [77] 0 0
Culiacán
Country [78] 0 0
Mexico
State/province [78] 0 0
Durango
Country [79] 0 0
Mexico
State/province [79] 0 0
Guadalajara
Country [80] 0 0
Mexico
State/province [80] 0 0
Merida
Country [81] 0 0
Mexico
State/province [81] 0 0
Mexico
Country [82] 0 0
Mexico
State/province [82] 0 0
Monterrey
Country [83] 0 0
Mexico
State/province [83] 0 0
México, D.F.
Country [84] 0 0
Mexico
State/province [84] 0 0
San Juan del Rio
Country [85] 0 0
Mexico
State/province [85] 0 0
Veracruz
Country [86] 0 0
Mexico
State/province [86] 0 0
Zapopan
Country [87] 0 0
New Zealand
State/province [87] 0 0
Grafton
Country [88] 0 0
New Zealand
State/province [88] 0 0
Tauranga
Country [89] 0 0
New Zealand
State/province [89] 0 0
Wellington
Country [90] 0 0
Philippines
State/province [90] 0 0
Quezon City
Country [91] 0 0
Philippines
State/province [91] 0 0
San Fernando City
Country [92] 0 0
Poland
State/province [92] 0 0
Kraków
Country [93] 0 0
Poland
State/province [93] 0 0
Rzeszów
Country [94] 0 0
Poland
State/province [94] 0 0
Warszawa
Country [95] 0 0
Romania
State/province [95] 0 0
Bucuresti
Country [96] 0 0
Romania
State/province [96] 0 0
Dobrosloveni
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Izhevsk
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Moscow
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Tomsk
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Ufa
Country [101] 0 0
Taiwan
State/province [101] 0 0
Taichung
Country [102] 0 0
Taiwan
State/province [102] 0 0
Tainan City
Country [103] 0 0
Taiwan
State/province [103] 0 0
Taipei
Country [104] 0 0
Thailand
State/province [104] 0 0
Bangkok
Country [105] 0 0
Thailand
State/province [105] 0 0
Chiang Mai
Country [106] 0 0
Thailand
State/province [106] 0 0
Chiang Rai
Country [107] 0 0
Thailand
State/province [107] 0 0
Hat Yai
Country [108] 0 0
Turkey
State/province [108] 0 0
Aydin
Country [109] 0 0
Turkey
State/province [109] 0 0
Bursa
Country [110] 0 0
Turkey
State/province [110] 0 0
Eskisehir
Country [111] 0 0
Turkey
State/province [111] 0 0
Istanbul
Country [112] 0 0
Turkey
State/province [112] 0 0
Izmir
Country [113] 0 0
Turkey
State/province [113] 0 0
Kocaeli
Country [114] 0 0
Turkey
State/province [114] 0 0
Kurupelit
Country [115] 0 0
Turkey
State/province [115] 0 0
Manisa
Country [116] 0 0
Turkey
State/province [116] 0 0
Trabzon
Country [117] 0 0
Ukraine
State/province [117] 0 0
Chernivts?
Country [118] 0 0
Ukraine
State/province [118] 0 0
Dnipro
Country [119] 0 0
Ukraine
State/province [119] 0 0
Kharkiv
Country [120] 0 0
Ukraine
State/province [120] 0 0
Kyiv
Country [121] 0 0
Ukraine
State/province [121] 0 0
Poltava
Country [122] 0 0
Ukraine
State/province [122] 0 0
Sumy
Country [123] 0 0
Ukraine
State/province [123] 0 0
Vinnytsia
Country [124] 0 0
Ukraine
State/province [124] 0 0
Zaporizhzhia
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Birmingham
Country [126] 0 0
United Kingdom
State/province [126] 0 0
London
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Middlesbrough
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Nottingham

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this research study is to evaluate the efficacy and safety of the drugs
dapagliflozin and saxagliptin in patients with Type 2 Diabetes who are aged 10 to below 18
years old and are currently taking metformin, insulin, or both drugs.

Dapagliflozin and saxagliptin are both approved for use in patients with Type 2 Diabetes aged
18 years or older. Dapagliflozin (alone or in combination with other antidiabetic drugs) is
available for use in adults in approximately 40 countries worldwide including the USA and
Europe. Saxagliptin (alone or in combination with other antidiabetic drugs) is available for
use in adults in approximately 90 countries worldwide. This study will assess how well
dapagliflozin and saxagliptin work by finding out how these treatments affect blood glucose
(sugar) levels compared to placebo (a pill that contains no active drug), in children and
adolescents. Dapagliflozin and saxagliptin are considered investigational products in this
study since while they have been approved for use in adults (patients 18 years or older),
they haven't been approved for children and adolescents due to lack of clinical studies in
this specific population.

Patients with Type 2 Diabetes have higher levels of blood glucose (sugar) than patients who
do not have this disease. The high level of sugar in the blood can lead to serious short-term
and long-term medical problems. The main goal of treating diabetic patients is to lower blood
glucose to a normal level. Lowering and controlling blood glucose help prevent or delay
complications of diabetes, such as heart disease, kidney, eye and nerve diseases, and the
possibility of amputation.

Dapagliflozin is a drug that helps to reduce blood glucose (sugar) levels by helping the
kidneys to remove excess glucose from the blood and excrete it in the urine. It prevents the
kidneys from returning glucose from the urine back into the bloodstream.

Saxagliptin increases insulin production when blood glucose levels are high. Insulin is a
hormone made by the pancreas that allows the body to use sugar (glucose) from the food that
is eaten for energy or to store glucose for future use. Saxagliptin helps to improve blood
sugar levels in response to a meal and between meals if blood glucose levels are not lowered
effectively. Saxagliptin does not work when the blood glucose is low. Saxagliptin also helps
to decrease the amount of sugar made by the body. Together, these processes reduce blood
glucose levels and help to control Type 2 Diabetes.

The subject will either receive one of the active study drugs or a placebo (a pill that looks
identical but contains inactive drug). This study will be double blind; this means that
neither the subject, nor the study doctor will know which treatment the subject will receive.

Which treatment the subject receives is decided by a computer, purely by chance; this is
called a "random assignment".

For this study, there will first be a screening phase of up to 6 months if Investigator
thinks that some of the screening tests can be repeated, followed by a 2 week lead in phase.
Thereafter there will be a 26W short-term treatment phase (W1-26), and a 26 W long-term
treatment phase (W27-52). Following this there will be a follow-up telephone call on week 56
and a post study visit at W104. At day 1 visit after the lead in phase the subject will be
randomly assigned to receive one of 3 treatments: dapagliflozin 5 mg, saxagliptin 2.5 mg or
placebo in a blinded manner. This treatment will continue up to week 14. Then after week 14,
and until the end of the study, the subject will be assigned to receive one of the following
5 treatments: dapagliflozin 5 mg, dapagliflozin 10 mg, saxagliptin 2.5 mg, saxagliptin 5 mg
or placebo in a blinded manner. The drugs assigned after week 14 will be the same drugs as at
Day 1, but some of the groups will receive them at a higher dose.Starting at W32 or W40,
i.e., after the end of the primary endpoints, patients with background medication of
metformin only, and an HbA1c value < 7.5% at W26 or W32, will undergo a third randomization.
Eligible subjects from the treatment arms will undergo the randomized withdrawal of
background medication, while eligible patients from the placebo arm will undergo, in addition
to randomized withdrawal of background medication a randomized switch to active treatment.

Short- and long-term period study visits can be delayed by a maximum of 11 months in total.
If the duration of investigational product administration is longer than 52 (+1) weeks, the
safety follow-up period should be shortened such that the complete study duration does not
exceed 104 weeks. The W104 visit should not be delayed.If more than 12 weeks elapse between
the HbA1c collection at W26 and the third rand at W32, or the HbA1c collection at W32 and the
third rand at W40, the subject should not go through this rand as the HbA1c value would no
longer be reliable to ascertain eligibility for the third rand
Trial website
https://clinicaltrials.gov/show/NCT03199053
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
information.center@astrazeneca.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03199053